Bank of New York Mellon
MPLT

Bank of New York Mellon’s MapLight Therapeutics MPLT Stock Holding History

Bank of New York Mellon’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
30,410
-9,055
-23% -$260K ﹤0.01% 3309
2026
Q1 		$802K Buy
39,465
+3,608
+10% +$64.5K ﹤0.01% 3343
2025
Q4 		$630K Buy
+35,857
New +$601K ﹤0.01% 3482

Other funds holding MPLT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MSWMA
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 16.2% 1-Year Est. Return
MPW
MA Private Wealth San Carlos, California $671M AUM 23.37% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Bank of New York Mellon's MPLT Position: Q2 2026 in Review

Bank of New York Mellon reduced its MapLight Therapeutics (MPLT) stake by 23% in Q2 2026, selling an estimated $260K and leaving 30,410 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3309.

Bank of New York Mellon first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Bank of New York Mellon held 30,410 shares of MapLight Therapeutics worth $1.09M as of Q2 2026.
  • Bank of New York Mellon sold 9,055 MapLight Therapeutics shares in Q2 2026, an estimated $260K.
  • MapLight Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3309 holding.
  • Bank of New York Mellon first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 27 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.